Overview

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

Status:
Completed

Trial end date:
2004-02-01

Target enrollment:

Participant gender:

Summary

The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.

Phase:

N/A

Details

Lead Sponsor:

Roxane Laboratories

Treatments:

Ropinirole